RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

Completed · Phase 2/Phase 3

Conditions studied: Venous Thromboembolism, Menstruation

In brief

A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.

Key facts

Study ID
NCT02829957
Run by
Indiana University
People needed
19
Starts
2016-09-01
Expected to finish
2020-02-13
Last updated by the study team
2023-11-13

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.